The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis

医学 肿瘤科 荟萃分析 免疫疗法 内科学 新辅助治疗 科克伦图书馆 不利影响 化疗 随机对照试验 卡铂 癌症 顺铂 乳腺癌
作者
Wenwu He,Li Wang,Changding Li,Xin Nie,Haojun Li,Jialong Li,Na Zhao,Haijun Chen,Xiaojie Miao,Yongtao Han,Qifeng Wang,Xuefeng Leng
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:14 被引量:9
标识
DOI:10.3389/fimmu.2023.1118902
摘要

Objective This systematic review and meta-analysis aimed to explore the efficacy and safety of neoadjuvant immunotherapy in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). Background Several studies have reported the outcomes of neoadjuvant immunotherapy in patients with ESCC. However, phase 3 randomized controlled trials (RCTs) with long-term outcomes and the comparison of different therapeutic strategies are lacking. Methods Studies involving patients with advanced ESCC treated with preoperative neoadjuvant immune checkpoint inhibitors (ICIs) were searched through PubMed, Embase, and Cochrane Library up to July 1, 2022. The outcomes were presented as proportions and pooled respectively by fixed or random effect model depending on the heterogeneity between studies. All analyses were performed using the R packages meta 5.5-0 and meta-for 3.4-0. Results Thirty trials involving 1406 patients were included in the meta-analysis. The pooled pathological complete response (pCR) rate for neoadjuvant immunotherapy was 0.30 (95% confidence interval [CI]: 0.26–0.33). The pCR rate of neoadjuvant immunotherapy combined with chemoradiotherapy (nICRT) was significantly higher than that of neoadjuvant immunotherapy combined with chemotherapy (nICT) (nICRT: 0.48, 95% CI: 0.31–0.65; nICT: 0.29, 95% CI: 0.26–0.33; p =0.03). No significant difference in efficacy was observed between the different chemotherapy agents and treatment cycles. The incidences of grade 1–2 and 3–4 treatment-related adverse events (TRAEs) were 0.71 (95% CI: 0.56–0.84) and 0.16 (95% CI: 0.09–0.25), respectively. Patients treated with nICRT and carboplatin had a higher incidence of grade 3–4 TRAEs compared with those treated with nICT (nICRT: 0.46, 95% CI: 0.17–0.77; nICT: 0.14, 95% CI: 0.07–0.22; p =0.03) and cisplatin (carboplatin: 0.33, 95% CI: 0.15–0.53; cisplatin: 0.04, 95% CI: 0.01–0.09; p <0.01). Conclusion Neoadjuvant immunotherapy has good efficacy and safety profiles in patients with locally advanced ESCC. Additional RCTs with long-term survival data are warranted.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanttt完成签到,获得积分10
刚刚
STEAM发布了新的文献求助10
1秒前
kay发布了新的文献求助10
2秒前
好人一生平安完成签到,获得积分10
2秒前
2秒前
2秒前
Yasong发布了新的文献求助10
2秒前
silentyw完成签到,获得积分10
2秒前
2秒前
lishixi完成签到,获得积分20
3秒前
YY完成签到,获得积分10
3秒前
lb完成签到,获得积分10
3秒前
过江春雷完成签到,获得积分10
3秒前
3秒前
dadaTwgdh完成签到,获得积分20
3秒前
178完成签到,获得积分10
4秒前
fantasy的应助被mmmm采纳,获得10
4秒前
且听风吟发布了新的文献求助10
4秒前
HiJ发布了新的文献求助10
4秒前
爱笑果汁完成签到 ,获得积分10
4秒前
4秒前
HiJ发布了新的文献求助10
4秒前
5秒前
千寻完成签到,获得积分10
5秒前
重要莹发布了新的文献求助10
5秒前
5秒前
包凡之发布了新的文献求助10
5秒前
zzz完成签到,获得积分10
5秒前
科研通AI2S的应助被HebingTang采纳,获得10
5秒前
5秒前
6秒前
6秒前
赘婿的应助被聚乙二醇采纳,获得10
6秒前
完美世界的应助被monkey采纳,获得10
7秒前
7秒前
小圆不头大完成签到,获得积分10
7秒前
7秒前
英俊的迎梦完成签到 ,获得积分10
8秒前
努力考研完成签到 ,获得积分10
8秒前
HiJ发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315